Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push
Executive Summary
Data presented at ASH show patients maintaining transfusion independence for years after infusion, months after bluebird won FDA approval for the beta-thalassemia gene therapy.